Mirodenafil

Drug Profile

Mirodenafil

Alternative Names: Aibishi; Bravonto; Mvix; SK-3530

Latest Information Update: 02 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SK Chemicals
  • Developer In2Gen; SK Chemicals
  • Class Erectile dysfunction therapies; Piperazines; Pyrimidinones; Small molecules; Sulfones
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erectile dysfunction

Most Recent Events

  • 29 Jan 2015 SK Chemicals completes a phase I pharmacokinetic trial in Renal impaired patients in South Korea (NCT01232010)
  • 05 Apr 2008 Pharmacokinetics data from a Phase-I trial in healthy volunteers presented at the 109th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2008)
  • 01 Aug 2007 First global launch of mirodenafil for Erectile dysfunction [South Korea]
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top